Categories
Credit Cards

Merrill Lynch Stick to The Buy Rating of theirs for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, and that is approximately 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the earliest quarter of 2021.

The current consensus among eleven TipRanks analysts is for a moderate Buy rating of shares in CVS Health, with an average price target of eighty four dolars.

The analysts price targets range from a high of hundred one dolars to a low of sixty one dolars.

In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is actually $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with four stars on a 0-5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It works through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management strategies. The retail or Long Term Care segment has offering of prescription medications and assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products as well as associated services, including medical, pharmacy, dental, behavioural health, medical control capabilities. The Corporate segment involves in providing management and administrative services. The company was created by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.

Leave a Reply

Your email address will not be published. Required fields are marked *